Daiichi Buys Biotech Antibody Technology From U.S. Firm
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo bought compound-combining technology from Seattle Genetics, a U.S. start-up biotech, for $4 million plus future payments if Daiichi brings drugs to market. Eventually, the Japanese drug maker plans to handle the biotech process on its own, but in the interim is to send antibodies and compounds to Seattle to have them combined and returned to Japan for research and development. Daiichi is interested in cancer-fighting compounds to combine with antibody drugs to make treatments more effective. (Click here for more - a subscripiton may be required
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.